Table 2. Feasibility of ALPPS.

Study	Number	FLR before stage 1 (mL)	FLR before stage 2 (mL)	FLR/SLV before stage 1 (ratio %)	FLR/SLV before stage 2 (ratio %)	Increase volume (mL)	Increase volume rate (ratio %)	Interval stages (days)	Kinetic growth (mL/day)	Stage 2 performed (ratio %)
Albert Chan	46	302.1 [181.9–524.0]	468.7 [243.0–795.7]	24.5 [15.7–37.1]	37.4 [20.5–56.9]	154.8 [18–405.0]	48.0 [8.0–133.2]	7 [6–70]	22.7 [1.2–81.0]	97.8
Zhang Wang	45	342 [221–488]	510 [384–712]	26.9 [17.9–39.2]	41.3[33.1–60.5]	NA	56.8 [8.3–103.5]	12 [6–28]	14.4 [5.4–50.6]	91.1
Daryl Chia	9	381.0 [280.0–422.0]	NA	16.1 [12.7–28.8]	NA	154.5 [85.5–166.0]	40.2 [22.1–65.3]	18.7 [5.6–23.5]	NA	77.8
Qiang Wang	10	364 [234–606]	632 [498–736]	31 [19–37]	47 [40–58]	210 [161–377]	53 [35–133]	28 [13–31]	NA	80
Xiujun Cai	12	378.7 [151.1–502.0]	479.3 [104.0–753.7]	29.2 [14.7–39.7]	38.5% [10.1–74.6]	132.1 [–47.1–366.7]	28.1 [–31.2–94.8]	10.5 [7–44]	NA	83.3
Chang Gung	5	NA	NA	28.8 [24.9–38.5]	45.3 [38.7–50.7]	NA	45.2 [31.8–75.3]	10 [8–14]	NA	NA
Vennarecci	13	421 [304–655]	723 [450–1,135]	23 [19–38]	23 [19–38]	NA	71.7	8 [7–10]	NA	87.5
D’Haese	35	420 [346–540]	639 [541–855]	NA	NA	206 [172–277]	47 [29–69]	11 [8–14]	23 [17–38]	NA
Björnsso	6	NA	NA	30 [12–41]	51 [35–62]	NA	73 [23–186]	8 [7–10]	NA	100

ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; FLR, future liver remnant; SLV, standard liver volume; NA, not available.